Biotech entity

MNCs

Company

Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention China, the most common co-covered peer. Each carries 3 original sources on average. We currently track 1 Biotech story that mention MNCs, all published on March 18, 2026.

Last mentioned: Mar 18, 2026

Entity pulse

Recent coverage · MNCs

1 story
7 avg impact
100% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.

  • 100% positive

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about MNCs

Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention China, the most common co-covered peer. Each carries 3 original sources on average. We currently track 1 Biotech story that mention MNCs, all published on March 18, 2026.

Stories tracked
1
Sources per story
3

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering MNCs. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Capital Pivot

    Major foreign venture funds announce new China-specific high-tech and biotech investment vehicles.

  2. Official Roadmap Launch

    China formally unveils the five-year roadmap focusing on New Quality Productive Forces.

  3. Policy Drafting

    Preliminary drafts of the 15th Five-Year Plan signal a shift toward high-tech self-reliance.

Stories mentioning MNCs 1

Pharma Positive

Foreign Capital Pivots to China's Biotech Sector Under New Five-Year Roadmap

China's launch of its 15th Five-Year Roadmap has triggered a strategic shift in foreign investment toward high-tech sectors, with biotechnology emerging as a primary beneficiary. Global pharmaceutical giants and venture funds are recalibrating their portfolios to align with Beijing’s 'New Quality Productive Forces' initiative.

3 sources

MNCs is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.